nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2B—Etoposide—lung cancer	0.412	0.555	CbGbCtD
Dexrazoxane—TOP2A—Teniposide—lung cancer	0.19	0.256	CbGbCtD
Dexrazoxane—TOP2A—Etoposide—lung cancer	0.0836	0.113	CbGbCtD
Dexrazoxane—TOP2A—Doxorubicin—lung cancer	0.057	0.0769	CbGbCtD
Dexrazoxane—TOP2B—mammary gland—lung cancer	0.00554	0.189	CbGeAlD
Dexrazoxane—TOP2B—respiratory system—lung cancer	0.00369	0.126	CbGeAlD
Dexrazoxane—TOP2B—bronchus—lung cancer	0.00304	0.104	CbGeAlD
Dexrazoxane—TOP2B—trachea—lung cancer	0.00273	0.0932	CbGeAlD
Dexrazoxane—TOP2B—cardiac atrium—lung cancer	0.00256	0.0875	CbGeAlD
Dexrazoxane—TOP2A—bronchus—lung cancer	0.00223	0.0763	CbGeAlD
Dexrazoxane—TOP2B—bone marrow—lung cancer	0.00216	0.0739	CbGeAlD
Dexrazoxane—TOP2B—lung—lung cancer	0.00196	0.0669	CbGeAlD
Dexrazoxane—TOP2B—Topotecan—Irinotecan—lung cancer	0.00165	0.264	CbGdCrCtD
Dexrazoxane—TOP2A—bone marrow—lung cancer	0.00159	0.0543	CbGeAlD
Dexrazoxane—TOP2A—lung—lung cancer	0.00144	0.0492	CbGeAlD
Dexrazoxane—TOP2B—lymph node—lung cancer	0.00134	0.0458	CbGeAlD
Dexrazoxane—TOP2A—lymph node—lung cancer	0.000986	0.0337	CbGeAlD
Dexrazoxane—TOP2B—Teniposide—Etoposide—lung cancer	0.000746	0.119	CbGdCrCtD
Dexrazoxane—TOP2A—Docetaxel—Paclitaxel—lung cancer	0.000376	0.0599	CbGdCrCtD
Dexrazoxane—TOP2A—Irinotecan—Topotecan—lung cancer	0.000322	0.0513	CbGdCrCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—RRAD—lung cancer	0.00031	0.104	CbGpPWpGaD
Dexrazoxane—TOP2A—Erlotinib—Gefitinib—lung cancer	0.000281	0.0447	CbGdCrCtD
Dexrazoxane—TOP2A—Topotecan—Irinotecan—lung cancer	0.000267	0.0426	CbGdCrCtD
Dexrazoxane—TOP2A—Etoposide—Teniposide—lung cancer	0.000266	0.0423	CbGdCrCtD
Dexrazoxane—TOP2A—Vindesine—Vinorelbine—lung cancer	0.000239	0.0381	CbGdCrCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—AXL—lung cancer	0.000235	0.0786	CbGpPWpGaD
Dexrazoxane—TOP2A—Podofilox—Teniposide—lung cancer	0.000203	0.0323	CbGdCrCtD
Dexrazoxane—TOP2A—Vindesine—Vinblastine—lung cancer	0.000191	0.0305	CbGdCrCtD
Dexrazoxane—TOP2A—Methotrexate—Pemetrexed—lung cancer	0.000191	0.0304	CbGdCrCtD
Dexrazoxane—TOP2A—Paclitaxel—Docetaxel—lung cancer	0.000188	0.0299	CbGdCrCtD
Dexrazoxane—TOP2A—Afatinib—Gefitinib—lung cancer	0.000184	0.0293	CbGdCrCtD
Dexrazoxane—TOP2A—Gefitinib—Erlotinib—lung cancer	0.00018	0.0287	CbGdCrCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—lung cancer	0.00013	0.0436	CbGpPWpGaD
Dexrazoxane—TOP2A—Vincristine—Vinorelbine—lung cancer	0.000129	0.0206	CbGdCrCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—HMGB2—lung cancer	0.000122	0.0408	CbGpPWpGaD
Dexrazoxane—TOP2A—Vinorelbine—Vinblastine—lung cancer	0.000121	0.0192	CbGdCrCtD
Dexrazoxane—TOP2A—Podofilox—Etoposide—lung cancer	0.00012	0.0192	CbGdCrCtD
Dexrazoxane—TOP2A—Teniposide—Etoposide—lung cancer	0.00012	0.0192	CbGdCrCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000116	0.000531	CcSEcCtD
Dexrazoxane—Alopecia—Docetaxel—lung cancer	0.000116	0.000529	CcSEcCtD
Dexrazoxane—Pruritus—Vinorelbine—lung cancer	0.000116	0.000528	CcSEcCtD
Dexrazoxane—Discomfort—Etoposide—lung cancer	0.000116	0.000528	CcSEcCtD
Dexrazoxane—Pain—Irinotecan—lung cancer	0.000116	0.000527	CcSEcCtD
Dexrazoxane—Constipation—Irinotecan—lung cancer	0.000116	0.000527	CcSEcCtD
Dexrazoxane—Mental disorder—Docetaxel—lung cancer	0.000115	0.000525	CcSEcCtD
Dexrazoxane—Myalgia—Paclitaxel—lung cancer	0.000115	0.000524	CcSEcCtD
Dexrazoxane—Erythema—Docetaxel—lung cancer	0.000115	0.000521	CcSEcCtD
Dexrazoxane—Malnutrition—Docetaxel—lung cancer	0.000115	0.000521	CcSEcCtD
Dexrazoxane—Decreased appetite—Gemcitabine—lung cancer	0.000114	0.000521	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000114	0.00052	CcSEcCtD
Dexrazoxane—Nausea—Topotecan—lung cancer	0.000114	0.000518	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000114	0.000518	CcSEcCtD
Dexrazoxane—Discomfort—Paclitaxel—lung cancer	0.000114	0.000518	CcSEcCtD
Dexrazoxane—Fatigue—Gemcitabine—lung cancer	0.000114	0.000517	CcSEcCtD
Dexrazoxane—Pain—Gemcitabine—lung cancer	0.000113	0.000513	CcSEcCtD
Dexrazoxane—Constipation—Gemcitabine—lung cancer	0.000113	0.000513	CcSEcCtD
Dexrazoxane—Nausea—Erlotinib—lung cancer	0.000113	0.000513	CcSEcCtD
Dexrazoxane—Pancytopenia—Methotrexate—lung cancer	0.000112	0.000512	CcSEcCtD
Dexrazoxane—Dry mouth—Paclitaxel—lung cancer	0.000112	0.000512	CcSEcCtD
Dexrazoxane—Diarrhoea—Vinorelbine—lung cancer	0.000112	0.000511	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000112	0.000509	CcSEcCtD
Dexrazoxane—Infection—Etoposide—lung cancer	0.000112	0.000509	CcSEcCtD
Dexrazoxane—Feeling abnormal—Irinotecan—lung cancer	0.000111	0.000507	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—SFN—lung cancer	0.000111	0.0372	CbGpPWpGaD
Dexrazoxane—Blood creatinine increased—Doxorubicin—lung cancer	0.000111	0.000506	CcSEcCtD
Dexrazoxane—Neutropenia—Methotrexate—lung cancer	0.000111	0.000504	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Irinotecan—lung cancer	0.000111	0.000503	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Etoposide—lung cancer	0.00011	0.000501	CcSEcCtD
Dexrazoxane—Infection—Paclitaxel—lung cancer	0.00011	0.000499	CcSEcCtD
Dexrazoxane—Dyspnoea—Cisplatin—lung cancer	0.000109	0.000498	CcSEcCtD
Dexrazoxane—Skin disorder—Etoposide—lung cancer	0.000109	0.000497	CcSEcCtD
Dexrazoxane—Feeling abnormal—Gemcitabine—lung cancer	0.000109	0.000494	CcSEcCtD
Dexrazoxane—Shock—Paclitaxel—lung cancer	0.000108	0.000494	CcSEcCtD
Dexrazoxane—Dizziness—Vinorelbine—lung cancer	0.000108	0.000494	CcSEcCtD
Dexrazoxane—Nervous system disorder—Paclitaxel—lung cancer	0.000108	0.000492	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Paclitaxel—lung cancer	0.000108	0.000492	CcSEcCtD
Dexrazoxane—Breast disorder—Doxorubicin—lung cancer	0.000107	0.000488	CcSEcCtD
Dexrazoxane—Anorexia—Etoposide—lung cancer	0.000107	0.000488	CcSEcCtD
Dexrazoxane—Skin disorder—Paclitaxel—lung cancer	0.000107	0.000488	CcSEcCtD
Dexrazoxane—Abdominal pain—Irinotecan—lung cancer	0.000107	0.000487	CcSEcCtD
Dexrazoxane—Body temperature increased—Irinotecan—lung cancer	0.000107	0.000487	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.000107	0.000487	CcSEcCtD
Dexrazoxane—Decreased appetite—Cisplatin—lung cancer	0.000107	0.000486	CcSEcCtD
Dexrazoxane—Pneumonia—Methotrexate—lung cancer	0.000106	0.000484	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Cisplatin—lung cancer	0.000106	0.000483	CcSEcCtD
Dexrazoxane—Anaemia—Docetaxel—lung cancer	0.000106	0.000482	CcSEcCtD
Dexrazoxane—Infestation NOS—Methotrexate—lung cancer	0.000106	0.000481	CcSEcCtD
Dexrazoxane—Infestation—Methotrexate—lung cancer	0.000106	0.000481	CcSEcCtD
Dexrazoxane—Depression—Methotrexate—lung cancer	0.000105	0.00048	CcSEcCtD
Dexrazoxane—Anorexia—Paclitaxel—lung cancer	0.000105	0.000479	CcSEcCtD
Dexrazoxane—Pain—Cisplatin—lung cancer	0.000105	0.000478	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000105	0.000477	CcSEcCtD
Dexrazoxane—Vomiting—Vinorelbine—lung cancer	0.000104	0.000475	CcSEcCtD
Dexrazoxane—Body temperature increased—Gemcitabine—lung cancer	0.000104	0.000474	CcSEcCtD
Dexrazoxane—TOP2A—Vinblastine—Vinorelbine—lung cancer	0.000104	0.0165	CbGdCrCtD
Dexrazoxane—TOP2A—Vincristine—Vinblastine—lung cancer	0.000103	0.0164	CbGdCrCtD
Dexrazoxane—Stomatitis—Methotrexate—lung cancer	0.000103	0.000469	CcSEcCtD
Dexrazoxane—Headache—Vinorelbine—lung cancer	0.000103	0.000468	CcSEcCtD
Dexrazoxane—Syncope—Docetaxel—lung cancer	0.000103	0.000468	CcSEcCtD
Dexrazoxane—Dysphagia—Doxorubicin—lung cancer	0.000103	0.000467	CcSEcCtD
Dexrazoxane—Leukopenia—Docetaxel—lung cancer	0.000103	0.000467	CcSEcCtD
Dexrazoxane—Feeling abnormal—Cisplatin—lung cancer	0.000101	0.000461	CcSEcCtD
Dexrazoxane—Loss of consciousness—Docetaxel—lung cancer	0.000101	0.000458	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.0001	0.000457	CcSEcCtD
Dexrazoxane—Dyspnoea—Etoposide—lung cancer	0.0001	0.000457	CcSEcCtD
Dexrazoxane—Somnolence—Etoposide—lung cancer	0.0001	0.000455	CcSEcCtD
Dexrazoxane—Cough—Docetaxel—lung cancer	9.99e-05	0.000455	CcSEcCtD
Dexrazoxane—Insomnia—Paclitaxel—lung cancer	9.97e-05	0.000454	CcSEcCtD
Dexrazoxane—Agranulocytosis—Methotrexate—lung cancer	9.86e-05	0.000449	CcSEcCtD
Dexrazoxane—Dyspnoea—Paclitaxel—lung cancer	9.83e-05	0.000448	CcSEcCtD
Dexrazoxane—Somnolence—Paclitaxel—lung cancer	9.8e-05	0.000446	CcSEcCtD
Dexrazoxane—Decreased appetite—Etoposide—lung cancer	9.78e-05	0.000445	CcSEcCtD
Dexrazoxane—Myalgia—Docetaxel—lung cancer	9.75e-05	0.000444	CcSEcCtD
Dexrazoxane—Pancytopenia—Doxorubicin—lung cancer	9.74e-05	0.000444	CcSEcCtD
Dexrazoxane—Nausea—Vinorelbine—lung cancer	9.74e-05	0.000443	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Etoposide—lung cancer	9.71e-05	0.000442	CcSEcCtD
Dexrazoxane—Body temperature increased—Cisplatin—lung cancer	9.7e-05	0.000442	CcSEcCtD
Dexrazoxane—Asthenia—Irinotecan—lung cancer	9.7e-05	0.000442	CcSEcCtD
Dexrazoxane—Fatigue—Etoposide—lung cancer	9.7e-05	0.000442	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	9.68e-05	0.000441	CcSEcCtD
Dexrazoxane—Pain—Etoposide—lung cancer	9.62e-05	0.000438	CcSEcCtD
Dexrazoxane—Constipation—Etoposide—lung cancer	9.62e-05	0.000438	CcSEcCtD
Dexrazoxane—Neutropenia—Doxorubicin—lung cancer	9.59e-05	0.000437	CcSEcCtD
Dexrazoxane—Decreased appetite—Paclitaxel—lung cancer	9.58e-05	0.000437	CcSEcCtD
Dexrazoxane—Dry mouth—Docetaxel—lung cancer	9.53e-05	0.000434	CcSEcCtD
Dexrazoxane—Haemoglobin—Methotrexate—lung cancer	9.53e-05	0.000434	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Paclitaxel—lung cancer	9.52e-05	0.000434	CcSEcCtD
Dexrazoxane—Fatigue—Paclitaxel—lung cancer	9.51e-05	0.000433	CcSEcCtD
Dexrazoxane—Haemorrhage—Methotrexate—lung cancer	9.48e-05	0.000432	CcSEcCtD
Dexrazoxane—Asthenia—Gemcitabine—lung cancer	9.45e-05	0.00043	CcSEcCtD
Dexrazoxane—Constipation—Paclitaxel—lung cancer	9.43e-05	0.000429	CcSEcCtD
Dexrazoxane—Pain—Paclitaxel—lung cancer	9.43e-05	0.000429	CcSEcCtD
Dexrazoxane—Pruritus—Gemcitabine—lung cancer	9.32e-05	0.000424	CcSEcCtD
Dexrazoxane—Infection—Docetaxel—lung cancer	9.28e-05	0.000423	CcSEcCtD
Dexrazoxane—Weight decreased—Doxorubicin—lung cancer	9.28e-05	0.000423	CcSEcCtD
Dexrazoxane—Feeling abnormal—Etoposide—lung cancer	9.27e-05	0.000422	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RRM1—lung cancer	9.26e-05	0.0309	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Irinotecan—lung cancer	9.25e-05	0.000421	CcSEcCtD
Dexrazoxane—Pneumonia—Doxorubicin—lung cancer	9.2e-05	0.000419	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Etoposide—lung cancer	9.2e-05	0.000419	CcSEcCtD
Dexrazoxane—Shock—Docetaxel—lung cancer	9.19e-05	0.000419	CcSEcCtD
Dexrazoxane—Nervous system disorder—Docetaxel—lung cancer	9.16e-05	0.000417	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Docetaxel—lung cancer	9.15e-05	0.000417	CcSEcCtD
Dexrazoxane—Infestation NOS—Doxorubicin—lung cancer	9.14e-05	0.000416	CcSEcCtD
Dexrazoxane—Infestation—Doxorubicin—lung cancer	9.14e-05	0.000416	CcSEcCtD
Dexrazoxane—Feeling abnormal—Paclitaxel—lung cancer	9.09e-05	0.000414	CcSEcCtD
Dexrazoxane—Skin disorder—Docetaxel—lung cancer	9.08e-05	0.000413	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Paclitaxel—lung cancer	9.02e-05	0.000411	CcSEcCtD
Dexrazoxane—Diarrhoea—Gemcitabine—lung cancer	9.01e-05	0.00041	CcSEcCtD
Dexrazoxane—Dizziness—Irinotecan—lung cancer	8.94e-05	0.000407	CcSEcCtD
Dexrazoxane—Urticaria—Etoposide—lung cancer	8.93e-05	0.000407	CcSEcCtD
Dexrazoxane—Stomatitis—Doxorubicin—lung cancer	8.91e-05	0.000406	CcSEcCtD
Dexrazoxane—Anorexia—Docetaxel—lung cancer	8.91e-05	0.000406	CcSEcCtD
Dexrazoxane—Body temperature increased—Etoposide—lung cancer	8.89e-05	0.000405	CcSEcCtD
Dexrazoxane—Abdominal pain—Etoposide—lung cancer	8.89e-05	0.000405	CcSEcCtD
Dexrazoxane—Asthenia—Cisplatin—lung cancer	8.81e-05	0.000401	CcSEcCtD
Dexrazoxane—Cardiac disorder—Methotrexate—lung cancer	8.8e-05	0.000401	CcSEcCtD
Dexrazoxane—Urticaria—Paclitaxel—lung cancer	8.76e-05	0.000399	CcSEcCtD
Dexrazoxane—Abdominal pain—Paclitaxel—lung cancer	8.72e-05	0.000397	CcSEcCtD
Dexrazoxane—Body temperature increased—Paclitaxel—lung cancer	8.72e-05	0.000397	CcSEcCtD
Dexrazoxane—Angiopathy—Methotrexate—lung cancer	8.6e-05	0.000392	CcSEcCtD
Dexrazoxane—Vomiting—Irinotecan—lung cancer	8.6e-05	0.000391	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Methotrexate—lung cancer	8.54e-05	0.000389	CcSEcCtD
Dexrazoxane—Agranulocytosis—Doxorubicin—lung cancer	8.53e-05	0.000389	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Docetaxel—lung cancer	8.51e-05	0.000388	CcSEcCtD
Dexrazoxane—Headache—Irinotecan—lung cancer	8.47e-05	0.000386	CcSEcCtD
Dexrazoxane—Insomnia—Docetaxel—lung cancer	8.45e-05	0.000385	CcSEcCtD
Dexrazoxane—Diarrhoea—Cisplatin—lung cancer	8.4e-05	0.000382	CcSEcCtD
Dexrazoxane—Alopecia—Methotrexate—lung cancer	8.38e-05	0.000382	CcSEcCtD
Dexrazoxane—Vomiting—Gemcitabine—lung cancer	8.37e-05	0.000381	CcSEcCtD
Dexrazoxane—Dyspnoea—Docetaxel—lung cancer	8.33e-05	0.000379	CcSEcCtD
Dexrazoxane—Somnolence—Docetaxel—lung cancer	8.31e-05	0.000378	CcSEcCtD
Dexrazoxane—Mental disorder—Methotrexate—lung cancer	8.31e-05	0.000378	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MSH6—lung cancer	8.25e-05	0.0276	CbGpPWpGaD
Dexrazoxane—Erythema—Methotrexate—lung cancer	8.25e-05	0.000376	CcSEcCtD
Dexrazoxane—Malnutrition—Methotrexate—lung cancer	8.25e-05	0.000376	CcSEcCtD
Dexrazoxane—Haemoglobin—Doxorubicin—lung cancer	8.25e-05	0.000376	CcSEcCtD
Dexrazoxane—Headache—Gemcitabine—lung cancer	8.25e-05	0.000376	CcSEcCtD
Dexrazoxane—Haemorrhage—Doxorubicin—lung cancer	8.21e-05	0.000374	CcSEcCtD
Dexrazoxane—Decreased appetite—Docetaxel—lung cancer	8.12e-05	0.00037	CcSEcCtD
Dexrazoxane—Oedema peripheral—Doxorubicin—lung cancer	8.09e-05	0.000368	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Docetaxel—lung cancer	8.07e-05	0.000367	CcSEcCtD
Dexrazoxane—Asthenia—Etoposide—lung cancer	8.07e-05	0.000367	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Doxorubicin—lung cancer	8.07e-05	0.000367	CcSEcCtD
Dexrazoxane—Fatigue—Docetaxel—lung cancer	8.06e-05	0.000367	CcSEcCtD
Dexrazoxane—Nausea—Irinotecan—lung cancer	8.03e-05	0.000366	CcSEcCtD
Dexrazoxane—Constipation—Docetaxel—lung cancer	7.99e-05	0.000364	CcSEcCtD
Dexrazoxane—Pain—Docetaxel—lung cancer	7.99e-05	0.000364	CcSEcCtD
Dexrazoxane—Pruritus—Etoposide—lung cancer	7.96e-05	0.000362	CcSEcCtD
Dexrazoxane—Asthenia—Paclitaxel—lung cancer	7.91e-05	0.00036	CcSEcCtD
Dexrazoxane—Nausea—Gemcitabine—lung cancer	7.82e-05	0.000356	CcSEcCtD
Dexrazoxane—Vomiting—Cisplatin—lung cancer	7.8e-05	0.000355	CcSEcCtD
Dexrazoxane—Pruritus—Paclitaxel—lung cancer	7.8e-05	0.000355	CcSEcCtD
Dexrazoxane—Feeling abnormal—Docetaxel—lung cancer	7.7e-05	0.000351	CcSEcCtD
Dexrazoxane—Diarrhoea—Etoposide—lung cancer	7.69e-05	0.00035	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Methotrexate—lung cancer	7.66e-05	0.000349	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Docetaxel—lung cancer	7.64e-05	0.000348	CcSEcCtD
Dexrazoxane—Anaemia—Methotrexate—lung cancer	7.63e-05	0.000347	CcSEcCtD
Dexrazoxane—Cardiac disorder—Doxorubicin—lung cancer	7.62e-05	0.000347	CcSEcCtD
Dexrazoxane—Diarrhoea—Paclitaxel—lung cancer	7.54e-05	0.000344	CcSEcCtD
Dexrazoxane—Angiopathy—Doxorubicin—lung cancer	7.45e-05	0.000339	CcSEcCtD
Dexrazoxane—Malaise—Methotrexate—lung cancer	7.44e-05	0.000339	CcSEcCtD
Dexrazoxane—Dizziness—Etoposide—lung cancer	7.44e-05	0.000339	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Doxorubicin—lung cancer	7.4e-05	0.000337	CcSEcCtD
Dexrazoxane—Abdominal pain—Docetaxel—lung cancer	7.39e-05	0.000336	CcSEcCtD
Dexrazoxane—Body temperature increased—Docetaxel—lung cancer	7.39e-05	0.000336	CcSEcCtD
Dexrazoxane—Leukopenia—Methotrexate—lung cancer	7.39e-05	0.000336	CcSEcCtD
Dexrazoxane—Dizziness—Paclitaxel—lung cancer	7.29e-05	0.000332	CcSEcCtD
Dexrazoxane—Nausea—Cisplatin—lung cancer	7.29e-05	0.000332	CcSEcCtD
Dexrazoxane—Alopecia—Doxorubicin—lung cancer	7.25e-05	0.00033	CcSEcCtD
Dexrazoxane—Cough—Methotrexate—lung cancer	7.2e-05	0.000328	CcSEcCtD
Dexrazoxane—Mental disorder—Doxorubicin—lung cancer	7.19e-05	0.000328	CcSEcCtD
Dexrazoxane—Vomiting—Etoposide—lung cancer	7.15e-05	0.000326	CcSEcCtD
Dexrazoxane—Erythema—Doxorubicin—lung cancer	7.15e-05	0.000325	CcSEcCtD
Dexrazoxane—Malnutrition—Doxorubicin—lung cancer	7.15e-05	0.000325	CcSEcCtD
Dexrazoxane—Headache—Etoposide—lung cancer	7.04e-05	0.000321	CcSEcCtD
Dexrazoxane—Myalgia—Methotrexate—lung cancer	7.03e-05	0.00032	CcSEcCtD
Dexrazoxane—Vomiting—Paclitaxel—lung cancer	7.01e-05	0.000319	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	6.98e-05	0.000318	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—APC—lung cancer	6.95e-05	0.0232	CbGpPWpGaD
Dexrazoxane—Discomfort—Methotrexate—lung cancer	6.94e-05	0.000316	CcSEcCtD
Dexrazoxane—Headache—Paclitaxel—lung cancer	6.91e-05	0.000315	CcSEcCtD
Dexrazoxane—TOP2A—Cytarabine—Gemcitabine—lung cancer	6.78e-05	0.0108	CbGdCrCtD
Dexrazoxane—Asthenia—Docetaxel—lung cancer	6.71e-05	0.000305	CcSEcCtD
Dexrazoxane—Infection—Methotrexate—lung cancer	6.69e-05	0.000305	CcSEcCtD
Dexrazoxane—Nausea—Etoposide—lung cancer	6.68e-05	0.000304	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Doxorubicin—lung cancer	6.63e-05	0.000302	CcSEcCtD
Dexrazoxane—Pruritus—Docetaxel—lung cancer	6.61e-05	0.000301	CcSEcCtD
Dexrazoxane—Nervous system disorder—Methotrexate—lung cancer	6.61e-05	0.000301	CcSEcCtD
Dexrazoxane—Anaemia—Doxorubicin—lung cancer	6.61e-05	0.000301	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Methotrexate—lung cancer	6.6e-05	0.0003	CcSEcCtD
Dexrazoxane—Nausea—Paclitaxel—lung cancer	6.55e-05	0.000298	CcSEcCtD
Dexrazoxane—Skin disorder—Methotrexate—lung cancer	6.54e-05	0.000298	CcSEcCtD
Dexrazoxane—Malaise—Doxorubicin—lung cancer	6.44e-05	0.000294	CcSEcCtD
Dexrazoxane—Anorexia—Methotrexate—lung cancer	6.42e-05	0.000292	CcSEcCtD
Dexrazoxane—Syncope—Doxorubicin—lung cancer	6.41e-05	0.000292	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—HES1—lung cancer	6.4e-05	0.0214	CbGpPWpGaD
Dexrazoxane—Leukopenia—Doxorubicin—lung cancer	6.4e-05	0.000291	CcSEcCtD
Dexrazoxane—Diarrhoea—Docetaxel—lung cancer	6.39e-05	0.000291	CcSEcCtD
Dexrazoxane—Loss of consciousness—Doxorubicin—lung cancer	6.28e-05	0.000286	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—KMT2A—lung cancer	6.25e-05	0.0209	CbGpPWpGaD
Dexrazoxane—Cough—Doxorubicin—lung cancer	6.24e-05	0.000284	CcSEcCtD
Dexrazoxane—Dizziness—Docetaxel—lung cancer	6.18e-05	0.000281	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Methotrexate—lung cancer	6.14e-05	0.000279	CcSEcCtD
Dexrazoxane—Insomnia—Methotrexate—lung cancer	6.09e-05	0.000277	CcSEcCtD
Dexrazoxane—Myalgia—Doxorubicin—lung cancer	6.08e-05	0.000277	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	6.04e-05	0.000275	CcSEcCtD
Dexrazoxane—Discomfort—Doxorubicin—lung cancer	6.01e-05	0.000274	CcSEcCtD
Dexrazoxane—Dyspnoea—Methotrexate—lung cancer	6.01e-05	0.000273	CcSEcCtD
Dexrazoxane—Somnolence—Methotrexate—lung cancer	5.99e-05	0.000273	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—lung cancer	5.96e-05	0.0199	CbGpPWpGaD
Dexrazoxane—Dry mouth—Doxorubicin—lung cancer	5.95e-05	0.000271	CcSEcCtD
Dexrazoxane—Vomiting—Docetaxel—lung cancer	5.94e-05	0.000271	CcSEcCtD
Dexrazoxane—Decreased appetite—Methotrexate—lung cancer	5.86e-05	0.000267	CcSEcCtD
Dexrazoxane—Headache—Docetaxel—lung cancer	5.85e-05	0.000267	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Methotrexate—lung cancer	5.82e-05	0.000265	CcSEcCtD
Dexrazoxane—TOP2A—Daunorubicin—Doxorubicin—lung cancer	5.81e-05	0.00927	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Doxorubicin—lung cancer	5.81e-05	0.00927	CbGdCrCtD
Dexrazoxane—TOP2A—Epirubicin—Doxorubicin—lung cancer	5.81e-05	0.00927	CbGdCrCtD
Dexrazoxane—Fatigue—Methotrexate—lung cancer	5.81e-05	0.000264	CcSEcCtD
Dexrazoxane—Infection—Doxorubicin—lung cancer	5.79e-05	0.000264	CcSEcCtD
Dexrazoxane—Pain—Methotrexate—lung cancer	5.76e-05	0.000262	CcSEcCtD
Dexrazoxane—Shock—Doxorubicin—lung cancer	5.74e-05	0.000261	CcSEcCtD
Dexrazoxane—Nervous system disorder—Doxorubicin—lung cancer	5.72e-05	0.00026	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—TOP1—lung cancer	5.72e-05	0.0191	CbGpPWpGaD
Dexrazoxane—Thrombocytopenia—Doxorubicin—lung cancer	5.71e-05	0.00026	CcSEcCtD
Dexrazoxane—Skin disorder—Doxorubicin—lung cancer	5.67e-05	0.000258	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—NKX2-1—lung cancer	5.57e-05	0.0186	CbGpPWpGaD
Dexrazoxane—Anorexia—Doxorubicin—lung cancer	5.56e-05	0.000253	CcSEcCtD
Dexrazoxane—Nausea—Docetaxel—lung cancer	5.55e-05	0.000253	CcSEcCtD
Dexrazoxane—Feeling abnormal—Methotrexate—lung cancer	5.55e-05	0.000253	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Methotrexate—lung cancer	5.51e-05	0.000251	CcSEcCtD
Dexrazoxane—Urticaria—Methotrexate—lung cancer	5.35e-05	0.000244	CcSEcCtD
Dexrazoxane—Body temperature increased—Methotrexate—lung cancer	5.32e-05	0.000242	CcSEcCtD
Dexrazoxane—Abdominal pain—Methotrexate—lung cancer	5.32e-05	0.000242	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Doxorubicin—lung cancer	5.31e-05	0.000242	CcSEcCtD
Dexrazoxane—Insomnia—Doxorubicin—lung cancer	5.28e-05	0.00024	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RHEB—lung cancer	5.21e-05	0.0174	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Doxorubicin—lung cancer	5.2e-05	0.000237	CcSEcCtD
Dexrazoxane—Somnolence—Doxorubicin—lung cancer	5.19e-05	0.000236	CcSEcCtD
Dexrazoxane—Decreased appetite—Doxorubicin—lung cancer	5.07e-05	0.000231	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Doxorubicin—lung cancer	5.04e-05	0.000229	CcSEcCtD
Dexrazoxane—Fatigue—Doxorubicin—lung cancer	5.03e-05	0.000229	CcSEcCtD
Dexrazoxane—Constipation—Doxorubicin—lung cancer	4.99e-05	0.000227	CcSEcCtD
Dexrazoxane—Pain—Doxorubicin—lung cancer	4.99e-05	0.000227	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—NODAL—lung cancer	4.94e-05	0.0165	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RRM1—lung cancer	4.94e-05	0.0165	CbGpPWpGaD
Dexrazoxane—TOP2A—Azacitidine—Gemcitabine—lung cancer	4.86e-05	0.00774	CbGdCrCtD
Dexrazoxane—Asthenia—Methotrexate—lung cancer	4.83e-05	0.00022	CcSEcCtD
Dexrazoxane—Feeling abnormal—Doxorubicin—lung cancer	4.81e-05	0.000219	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Doxorubicin—lung cancer	4.77e-05	0.000217	CcSEcCtD
Dexrazoxane—Pruritus—Methotrexate—lung cancer	4.77e-05	0.000217	CcSEcCtD
Dexrazoxane—Urticaria—Doxorubicin—lung cancer	4.63e-05	0.000211	CcSEcCtD
Dexrazoxane—Abdominal pain—Doxorubicin—lung cancer	4.61e-05	0.00021	CcSEcCtD
Dexrazoxane—Body temperature increased—Doxorubicin—lung cancer	4.61e-05	0.00021	CcSEcCtD
Dexrazoxane—Diarrhoea—Methotrexate—lung cancer	4.61e-05	0.00021	CcSEcCtD
Dexrazoxane—Dizziness—Methotrexate—lung cancer	4.45e-05	0.000203	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—PPP2R1B—lung cancer	4.4e-05	0.0147	CbGpPWpGaD
Dexrazoxane—Vomiting—Methotrexate—lung cancer	4.28e-05	0.000195	CcSEcCtD
Dexrazoxane—Headache—Methotrexate—lung cancer	4.22e-05	0.000192	CcSEcCtD
Dexrazoxane—Asthenia—Doxorubicin—lung cancer	4.18e-05	0.000191	CcSEcCtD
Dexrazoxane—Pruritus—Doxorubicin—lung cancer	4.13e-05	0.000188	CcSEcCtD
Dexrazoxane—Nausea—Methotrexate—lung cancer	4e-05	0.000182	CcSEcCtD
Dexrazoxane—Diarrhoea—Doxorubicin—lung cancer	3.99e-05	0.000182	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—lung cancer	3.93e-05	0.0131	CbGpPWpGaD
Dexrazoxane—Dizziness—Doxorubicin—lung cancer	3.86e-05	0.000176	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RARB—lung cancer	3.84e-05	0.0128	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—lung cancer	3.84e-05	0.0128	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—lung cancer	3.72e-05	0.0124	CbGpPWpGaD
Dexrazoxane—Vomiting—Doxorubicin—lung cancer	3.71e-05	0.000169	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—AHR—lung cancer	3.69e-05	0.0123	CbGpPWpGaD
Dexrazoxane—Headache—Doxorubicin—lung cancer	3.65e-05	0.000166	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MYC—lung cancer	3.63e-05	0.0121	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—EGFR—lung cancer	3.55e-05	0.0119	CbGpPWpGaD
Dexrazoxane—Nausea—Doxorubicin—lung cancer	3.46e-05	0.000158	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—lung cancer	3.36e-05	0.0112	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—ADCY1—lung cancer	3.29e-05	0.011	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ANXA1—lung cancer	2.99e-05	0.00999	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—lung cancer	2.98e-05	0.00996	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—APP—lung cancer	2.84e-05	0.00947	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—TYMS—lung cancer	2.77e-05	0.00925	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—JUNB—lung cancer	2.69e-05	0.00897	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RB1—lung cancer	2.67e-05	0.00891	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—lung cancer	2.44e-05	0.00815	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—lung cancer	2.27e-05	0.0076	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RAF1—lung cancer	2.27e-05	0.00757	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—lung cancer	2.14e-05	0.00714	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—AVP—lung cancer	2.12e-05	0.00707	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—lung cancer	2.1e-05	0.00701	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TYMS—lung cancer	2.01e-05	0.00673	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—lung cancer	1.98e-05	0.00662	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—FOXM1—lung cancer	1.95e-05	0.00651	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—lung cancer	1.93e-05	0.00644	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—lung cancer	1.92e-05	0.0064	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RB1—lung cancer	1.88e-05	0.00627	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FGFR1—lung cancer	1.77e-05	0.00593	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—FOXM1—lung cancer	1.74e-05	0.00582	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN2A—lung cancer	1.65e-05	0.00551	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—PPP2R1B—lung cancer	1.61e-05	0.00539	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MYC—lung cancer	1.59e-05	0.00531	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—LMNA—lung cancer	1.54e-05	0.00515	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—APC—lung cancer	1.54e-05	0.00514	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGF—lung cancer	1.52e-05	0.00508	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—PPP2R1B—lung cancer	1.44e-05	0.00482	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—lung cancer	1.43e-05	0.00479	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—lung cancer	1.43e-05	0.00477	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND1—lung cancer	1.39e-05	0.00466	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—LMNA—lung cancer	1.38e-05	0.0046	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAP2K1—lung cancer	1.36e-05	0.00455	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1A—lung cancer	1.35e-05	0.00451	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—lung cancer	1.3e-05	0.00436	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—lung cancer	1.21e-05	0.00405	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RAF1—lung cancer	1.21e-05	0.00404	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—lung cancer	1.2e-05	0.00399	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—lung cancer	1.17e-05	0.00391	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYC—lung cancer	1.12e-05	0.00374	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—lung cancer	1.08e-05	0.00363	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—lung cancer	1.06e-05	0.00353	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—lung cancer	1.05e-05	0.00352	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—lung cancer	1.02e-05	0.00341	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—lung cancer	1.02e-05	0.00341	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—TYMS—lung cancer	1.02e-05	0.00339	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—JUN—lung cancer	1.01e-05	0.00338	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PTEN—lung cancer	9.79e-06	0.00327	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	9.72e-06	0.00325	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	9.45e-06	0.00316	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—EP300—lung cancer	9.33e-06	0.00312	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	9.21e-06	0.00308	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—BIRC5—lung cancer	9.13e-06	0.00305	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TYMS—lung cancer	9.08e-06	0.00303	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	8.71e-06	0.00291	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	8.47e-06	0.00283	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	8.29e-06	0.00277	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—BIRC5—lung cancer	8.16e-06	0.00273	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TERT—lung cancer	7.91e-06	0.00264	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	7.83e-06	0.00262	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	7.19e-06	0.0024	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	6.96e-06	0.00232	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RB1—lung cancer	6.88e-06	0.0023	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—lung cancer	6.68e-06	0.00223	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RB1—lung cancer	6.16e-06	0.00206	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—IL6—lung cancer	6.11e-06	0.00204	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN2A—lung cancer	6.05e-06	0.00202	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	5.87e-06	0.00196	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN2A—lung cancer	5.41e-06	0.00181	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MDM2—lung cancer	5.25e-06	0.00175	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND1—lung cancer	5.11e-06	0.00171	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1A—lung cancer	4.95e-06	0.00165	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—EP300—lung cancer	4.71e-06	0.00157	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND1—lung cancer	4.57e-06	0.00153	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1A—lung cancer	4.42e-06	0.00148	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MAPK3—lung cancer	4.22e-06	0.00141	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—EP300—lung cancer	4.21e-06	0.00141	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYC—lung cancer	4.1e-06	0.00137	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MAPK3—lung cancer	3.77e-06	0.00126	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYC—lung cancer	3.67e-06	0.00123	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—lung cancer	3.01e-06	0.00101	CbGpPWpGaD
